Latest Pathology News

Page 7 of 10
Sonic Healthcare delivered solid FY2025 results with 8% revenue growth and a 7% rise in net profit, setting the stage for an anticipated 19% earnings per share increase in FY2026.
Ada Torres
Ada Torres
21 Aug 2025
Pro Medicus has delivered a landmark FY25 with soaring revenue and profit, driven by major contract wins and strategic cloud deployments. The company’s expanding North American footprint and AI initiatives set the stage for sustained growth.
Victor Sage
Victor Sage
14 Aug 2025
Charter Hall Social Infrastructure REIT (CQE) reported steady FY25 results with a 15.2 cents per unit distribution and announced a 10.5% increase in guidance for FY26, underpinned by strategic acquisitions and a robust debt refinancing.
Eva Park
Eva Park
11 Aug 2025
Charter Hall Social Infrastructure REIT (CQE) reported solid FY25 results, highlighted by strategic acquisitions, a successful $900 million debt refinancing, and a 10.5% lift in distribution guidance for FY26.
Eva Park
Eva Park
11 Aug 2025
Charter Hall Social Infrastructure REIT has reported a statutory profit of $71 million for FY25, reversing last year’s loss, while advancing its portfolio through key acquisitions and refinancing.
Eva Park
Eva Park
11 Aug 2025
Optiscan Imaging Ltd has launched its first in-human breast cancer study and unveiled a new veterinary imaging device, while securing a key US collaboration to support FDA submissions.
Ada Torres
Ada Torres
31 July 2025
Invion Limited has secured a $20,000 grant to support its anogenital cancer trial and progressed its skin cancer study with promising early results, while raising approximately $1 million through a Loyalty Option Entitlement Offer.
Ada Torres
Ada Torres
31 July 2025
Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.
Ada Torres
Ada Torres
31 July 2025
Alterity Therapeutics has secured U.S. FDA Fast Track designation for its drug ATH434 targeting Multiple System Atrophy, supported by promising Phase 2 clinical trial data showing slowed disease progression and a solid safety profile.
Ada Torres
Ada Torres
30 July 2025
Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.
Ada Torres
Ada Torres
30 July 2025
Patrys Limited has completed a modest capital raise and restructured its leadership as it advances its deoxymab antibody program, with a larger entitlement offer announced to fund clinical development and business growth.
Ada Torres
Ada Torres
29 July 2025
Alterity Therapeutics has reported encouraging topline results from its open-label Phase 2 trial of ATH434 in advanced Multiple System Atrophy, showing slowed disease progression and biomarker stabilization.
Ada Torres
Ada Torres
28 July 2025